Exposure to polymers reverses inhibition of pulmonary surfactant by serum, meconium, or cholesterol in the captive bubble surfactometer
- PMID: 23062337
- PMCID: PMC3471484
- DOI: 10.1016/j.bpj.2012.08.024
Exposure to polymers reverses inhibition of pulmonary surfactant by serum, meconium, or cholesterol in the captive bubble surfactometer
Abstract
Dysfunction of pulmonary surfactant in the lungs is associated with respiratory pathologies such as acute respiratory distress syndrome or meconium aspiration syndrome. Serum, cholesterol, and meconium have been described as inhibitory agents of surfactant's interfacial activity once these substances appear in alveolar spaces during lung injury and inflammation. The deleterious action of these agents has been only partly evaluated under physiologically relevant conditions. We have optimized a protocol to assess surfactant inhibition by serum, cholesterol, or meconium in the captive bubble surfactometer. Specific measures of surface activity before and after native surfactant was exposed to inhibitors included i), film formation, ii), readsorption of material from surface-associated reservoirs, and iii), interfacial film dynamics during compression-expansion cycling. Results show that serum creates a steric barrier that impedes surfactant reaching the interface. A mechanical perturbation of this barrier allows native surfactant to compete efficiently with serum to form a highly surface-active film. Exposure of native surfactant to cholesterol or meconium, on the other hand, modifies the compressibility of surfactant films though optimal compressibility properties recover on repetitive compression-expansion cycling. Addition of polymers like dextran or hyaluronic acid to surfactant fully reverses inhibition by serum. These polymers also prevent surfactant inhibition by cholesterol or meconium, suggesting that the protective action of polymers goes beyond the mere enhancement of interfacial adsorption as described by depletion force theories.
Copyright © 2012 Biophysical Society. Published by Elsevier Inc. All rights reserved.
Figures






Similar articles
-
Inhibition and counterinhibition of Surfacen, a clinical lung surfactant of natural origin.PLoS One. 2018 Sep 20;13(9):e0204050. doi: 10.1371/journal.pone.0204050. eCollection 2018. PLoS One. 2018. PMID: 30235278 Free PMC article.
-
Meconium impairs pulmonary surfactant by a combined action of cholesterol and bile acids.Biophys J. 2011 Feb 2;100(3):646-655. doi: 10.1016/j.bpj.2010.12.3715. Biophys J. 2011. PMID: 21281579 Free PMC article.
-
Pulmonary surfactant function is abolished by an elevated proportion of cholesterol.Biochim Biophys Acta. 2005 Oct 15;1737(1):27-35. doi: 10.1016/j.bbalip.2005.09.002. Epub 2005 Oct 10. Biochim Biophys Acta. 2005. PMID: 16216549
-
Surface activity in situ, in vivo, and in the captive bubble surfactometer.Comp Biochem Physiol A Mol Integr Physiol. 2001 May;129(1):195-207. doi: 10.1016/s1095-6433(01)00316-6. Comp Biochem Physiol A Mol Integr Physiol. 2001. PMID: 11369544 Review.
-
Formation and structure of surface films: captive bubble surfactometry.Biochim Biophys Acta. 1998 Nov 19;1408(2-3):180-202. doi: 10.1016/s0925-4439(98)00067-2. Biochim Biophys Acta. 1998. PMID: 9813315 Review.
Cited by
-
Evaluating the Impact of Hydrophobic Silicon Dioxide in the Interfacial Properties of Lung Surfactant Films.Environ Sci Technol. 2022 Jun 7;56(11):7308-7318. doi: 10.1021/acs.est.1c06885. Epub 2022 Jan 25. Environ Sci Technol. 2022. PMID: 35078318 Free PMC article.
-
Clinical and biological role of secretory phospholipase A2 in acute respiratory distress syndrome infants.Crit Care. 2013 Jul 24;17(4):R163. doi: 10.1186/cc12842. Crit Care. 2013. PMID: 23883784 Free PMC article.
-
A recipe for a good clinical pulmonary surfactant.Biomed J. 2022 Aug;45(4):615-628. doi: 10.1016/j.bj.2022.03.001. Epub 2022 Mar 8. Biomed J. 2022. PMID: 35272060 Free PMC article. Review.
-
Inhibition and counterinhibition of Surfacen, a clinical lung surfactant of natural origin.PLoS One. 2018 Sep 20;13(9):e0204050. doi: 10.1371/journal.pone.0204050. eCollection 2018. PLoS One. 2018. PMID: 30235278 Free PMC article.
-
In vitro and in vivo characterization of poractant alfa supplemented with budesonide for safe and effective intratracheal administration.Pediatr Res. 2017 Dec;82(6):1056-1063. doi: 10.1038/pr.2017.171. Epub 2017 Aug 23. Pediatr Res. 2017. PMID: 28723887
References
-
- Pérez-Gil J. Structure of pulmonary surfactant membranes and films: the role of proteins and lipid-protein interactions. Biochim. Biophys. Acta. 2008;1778:1676–1695. - PubMed
-
- Serrano A.G., Pérez-Gil J. Protein-lipid interactions and surface activity in the pulmonary surfactant system. Chem. Phys. Lipids. 2006;141:105–118. - PubMed
-
- Taeusch H.W. Treatment of acute (Adult) respiratory distress syndrome. The holy grail of surfactant therapy. Biol. Neonate. 2000;77(Suppl 1):2–8. - PubMed
-
- Ware L.B., Matthay M.A. The acute respiratory distress syndrome. N. Engl. J. Med. 2000;342:1334–1349. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical